Mdxhealth Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
MDxhealth SA (NASDAQ: MDXH) said Nasdaq notified it on June 30, 2026 that it is not meeting the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The company has until Dec. 28, 2026 to regain compliance by having a $1.00+ closing bid for 10 straight business days. Operations are unaffected; reverse split is possible.
How this was made
The 30-second read
Why it matters
The company has 180 calendar days (until Dec. 28, 2026) to regain compliance by achieving a $1.00 closing bid for at least 10 consecutive business days; otherwise it may face delisting or seek additional time.
Market read
This is a concrete listing-compliance catalyst that can drive trading volatility and increase the probability of corporate actions (e.g., reverse split) to restore bid price.
What to watch
Traders should watch for any concurrent financing, share repurchase, or reverse-split authorization details that could change the compliance path before the 10-consecutive-business-day test window.
Background
Nasdaq requires a minimum $1.00 bid price for continued listing; failure persisting for 30 consecutive business days triggers deficiency status.
Ticker impact
MDxhealth received a Nasdaq minimum bid price deficiency notice and has until Dec. 28, 2026 to regain $1.00 compliance.
Near-term downside risk from delisting overhang; volatility likely around any reverse-split decision or compliance updates.
The filing is a primary exchange notification (not a recap) and explicitly frames a compliance deadline and potential delisting, which typically pressures microcap liquidity and sentiment.
Market effects
Adds to the broader risk premium for small-cap healthcare diagnostics names trading near $1, where reverse-split headlines can cluster.
Limited direct regional spillover; mainly affects US-listed microcap sentiment and liquidity.
Low—primarily a US listing compliance event with limited cross-border fundamentals impact.
Counterpoint
Because the company states the notification does not impact listing “at this time,” the market may overreact and the stock could stabilize if bid price quickly recovers above $1.
Key entities
- companyMDxhealth SA
Nasdaq Capital Market issuer that received the minimum bid price deficiency notification.
- regulator/venueNasdaq Stock Market LLC
Listing venue issuing the deficiency notice under Listing Rules 5550(a)(2) and 5810.
